...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
【24h】

Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.

机译:盐酸坦索罗辛对前列腺增生患者下尿路症状和生活质量的影响。使用打分评分进行评估。

获取原文
获取原文并翻译 | 示例

摘要

Benign prostatic hyperplasia (BPH) affects quality of life (QOL), and the goal of treatment is to improve lower urinary tract symptoms (LUTS), thus improving patient QOL. However, the international prostate symptom score (IPSS) used for evaluating LUTS does not always reflect the level of patient bother, and improvement in the IPSS score does not always reflect patient QOL. Therefore, in the present study, we observed the therapeutic effects of alpha(1)-blockers on IPSS, QOL index, and the bother score for individual symptoms. Ninety-three men diagnosed with BPH who had not yet been treated were enrolled (mean age 70 years). The IPSS, QOL index, and bother score for each symptom of IPSS (maximum 42 points, 7 grades, from 0 to 6: not at all bothersome, not bothersome, not much bother, neutral, a little bothersome, somewhat bothersome, very bothersome) were assessed in order to examine the correlation between LUTS and QOL. After treatment with tamsulosin hydrochloride 0.2 mg/day for 4 weeks, the change in each IPSS and bother score and the correlation was reassessed. Furthermore, the contribution of improvements in each symptom score and bother score to improvement in QOL index was examined using a path analysis model. On the IPSS at initial evaluation, the score was highest for slow stream. The bother scores were high for slow stream, nocturia, and daytime frequency. For slow stream, patients with a high IPSS score also had a high bother score, but for nocturia, there was a large discrepancy between the IPSS and bother score. After treatment, total IPSS, QOL and total bother scores were significantly improved (p <0.01). Improvements in all individual symptom scores and bother scores were also observed (p <0.01). The most predictable symptom for improvement in QOL after treatment was the improvement in the bother score for nocturia (F test; p <0.01). Treatment with tamsulosin hydrochloride showed significant improvement of each IPSS and the bother score. For nocturia, there was a large discrepancy between the IPSS and bother score. After treatment, the improvement in bother score for nocturia showed the strongest contribution to improvement in QOL. The present study suggests that in addition to the IPSS, the evaluation of bother score for each symptom may be necessary in the management for patients with LUTS suggestive of BPH.
机译:良性前列腺增生(BPH)影响生活质量(QOL),治疗的目标是改善下尿路症状(LUTS),从而改善患者的QOL。但是,用于评估LUTS的国际前列腺症状评分(IPSS)并不总是反映出患者的困扰程度,IPSS评分的改善并不总是反映出患者的QOL。因此,在本研究中,我们观察到了α(1)受体阻滞剂对IPSS,QOL指数和各个症状的困扰评分的治疗作用。入选了93名未经治疗的BPH男性(平均年龄70岁)。每个IPSS症状的IPSS,QOL指数和烦恼分数(最高42分,7个等级,从0到6:完全不烦,不烦,不烦,中性,有点烦,有点烦,非常烦为了评估LUTS和QOL之间的相关性,对进行了评估。用盐酸坦索罗辛0.2 mg /天治疗4周后,重新评估每个IPSS的变化和困扰评分以及相关性。此外,使用路径分析模型检查了每个症状评分和打扰评分的改善对QOL指数改善的贡献。在IPSS初始评估中,慢流得分最高。对于慢流,夜尿症和白天频率,打扰分数很高。对于慢流,IPSS评分高的患者也有较高的烦恼评分,但对于夜尿症,IPSS和烦恼评分之间存在较大差异。治疗后,总IPSS,生活质量(QOL)和总打扰评分均得到明显改善(p <0.01)。还观察到所有个体症状评分和打扰评分都有改善(p <0.01)。治疗后QOL改善最可预测的症状是夜尿困扰评分的改善(F检验; p <0.01)。盐酸坦索罗辛治疗显示每个IPSS都有显着改善,并且打扰评分。对于夜尿症,IPSS和打扰分数之间存在很大差异。治疗后,夜尿症困扰评分的改善显示出对生活质量改善的最大贡献。本研究表明,除了IPSS之外,对于提示BPH的LUTS患者的治疗,可能还需要评估每种症状的困扰评分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号